Mamantia, Joseph .

HRN: 23-36-20  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/21/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/21/2023
07/28/2023
IV
300
Q6
Peritonsillar Abscess
Waiting Final Action 
07/21/2023
CEFTRIAXONE 1G (VIAL)
07/21/2023
07/28/2023
IV
2g
Od
Peritonsillar Abscess
Waiting Final Action 
07/29/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
07/29/2023
08/04/2023
IV
1.5g
Q6h
Peritonsillar Abscess
Waiting Final Action 
07/30/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/30/2023
08/06/2023
IV
300mg
Q6
Peritonsillar Abscess
Waiting Final Action 
08/06/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
08/06/2023
08/20/2023
IVT
4.5g
Q6
Sepsis
Checking Final Appropriateness 
08/13/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
08/13/2023
08/20/2023
IV
600mg Now Then 300mg
Q6
Peritonsillar Abcess; Sepsis
Checking Final Appropriateness 
08/13/2023
ERYTHROMYCIN 0.5%, 3.5G EYE OINTMENT (TUBE)
08/13/2023
08/20/2023
OPTIC
0.5%
BID
T/c Midline Granuloma
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: